Key result
Silencing ET-1 inhibits lung cancer growth and invasion, particularly when combined with Endostar.
Why the study?
Endothelin-1 is a key cardiovascular regulatory factor with unclear effects on lung cancer cell proliferation, invasion, and sensitivity to Endostar treatment.
Silencing ET-1 in lung cancer models inhibits tumor proliferation and invasion, and increases sensitivity to the anti-angiogenic drug recombinant human endostatin.
ET-1 silencing may enhance endostatin effects in lung cancer models; hypothesis-generating and should not change practice.
Endothelin-1 (ET-1), which exists not only in the vascular endothelium but is also widely present in various tissues and cells, is an important cardiovascular regulatory factor that serves an important role in maintaining the basal vascular tone and homeostasis in the cardiovascular system. In the present study, the ET‑1 gene was silenced by RNA interference, and the effects on lung cancer cell proliferation and tumor cell invasion were then detected by Cell Counting kit‑8 and Transwell assays. In addition, the expression of apoptosis, growth and invasion‑associated proteins, including RhoA/C, vascular endothelial growth factor, pigment epithelium-derived factor, AKT, E‑cadherin and cyclooxygenase-2 was evaluated by western blotting upon silencing ET‑1. In the present study, Endostar, a recombinant human endostatin injectable drug, was also used, and it was assessed whether the sensitivity of tumor cells to this drug could be increased by silencing ET‑1. Both in vivo and in vivo tests were carried out in the present study. The experimental data indicated that ET‑1 silencing can inhibit tumor cell proliferation and invasion, particularly in the presence of Endostar.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2017) studied Lung cancer (n=12). ET-1 silencing (shRNA) vs. Empty vector was evaluated on Tumor growth in vivo (p=<0.05). Silencing endothelin-1 significantly inhibited lung cancer cell proliferation, invasion, and in vivo tumor growth, particularly when combined with Endostar.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: